These are the stocks posting the largest moves before the bell.Market Insiderread more
Mnuchin tells CNBC he's confident President Trump and China's Xi Jinping can make progress in stalled trade talks.World Economyread more
U.S. stock index futures jumped Wednesday morning after Treasury Secretary Steven Mnuchin told CNBC that the U.S. and China were close to reaching a trade deal.US Marketsread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and its hurting America," he told Yahoo Finance Tuesday.Economyread more
President Donald Trump's administration hopes additional sanctions on Iran will force the country to negotiate.Politicsread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
Mortgage application volume was 40% higher than a year ago, largely because lower rates are strengthening the refinance market.Real Estateread more
Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
Bitcoin surged as high as $12,919 in early morning trade Wednesday, to its highest level since January 2018.Technologyread more
AbbVie's deal to buy Allergan for about $63 billion is a "nice exit from a tough situation," RBC Capital Markets analyst Randall Stanicky says.Biotech and Pharmaceuticalsread more
Omada Health just raised $73 million at a valuation of around $600 million as it seeks to expand its digital health offerings.Technologyread more
Check out the companies making headlines after the bell:
Tilray shares surged as much as 19 percent after hours after the company announced it entered into a $100 million joint venture with AB InBev. The beer brewer and Tilray will study non-alcoholic cannabis-based beverages in Canada. The joint venture, in which both companies will invest $50 million each, will study non-alcoholic beverages containing THC, the intoxicating chemical compound in marijuana, as well as CBD, the non-psychoactive compound.
Spectrum Pharmaceuticals shares plummeted nearly 34 percent during after hours trading upon the news that the U.S. Food and Drug Administration did not grant Breakthrough Therapy Designation to the drug poziotinib. This treats patients with non-small cell lung cancer. This designation would've expedited the review of the drug.
Steelcase shares rose as much as 2.3 percent during after hours trading as the company beat expectations on its top and bottom lines. The company earned 36 cents per share, while analysts expected 30 cents per share. It also beat estimates of $898 million in revenue, reporting $901 million this quarter.